FAT2 mutation is associated with better prognosis and responsiveness to immunotherapy in uterine corpus endometrial carcinoma.

Wang, Zhe; Xing, Linan; Huang, Yujie; Han, Peilin

Wang, Zhe; Xing, Linan; Huang, Yujie; Han, Peilin.

Afiliación

Wang Z; Department of Gynecology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, People's Republic of China.
Xing L; Department of Gynecology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, People's Republic of China.
Huang Y; Department of Gynecology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, People's Republic of China.
Han P; Department of Gynecology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, People's Republic of China.

Cancer Med ; 12(3): 3797-3811, 2023 02.

Article en En | MEDLINE | ID: mdl-36812126

Asunto(s)

Carcinoma Endometrioide; Neoplasias Endometriales; Humanos; Femenino; Inmunoterapia; Pronóstico; Carcinogénesis; Transformación Celular Neoplásica; Microambiente Tumoral; Cadherinas

Palabras clave

FAT2 mutation; immunotherapy; prognosis; uterine corpus endometrial carcinoma

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias Endometriales / Carcinoma Endometrioide Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Female / Humans Idioma: En Revista: Cancer Med Año: 2023 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google